# Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly
> Note: PeptIQ is not a medical provider. Cagrilintide / CagriSema regulatory status can change by region. This is educational dosing literacy from public trial communications — not a prescription.
Cagrilintide is Novo Nordisk's long-acting amylin analogue. Most people meet it inside CagriSema — the once-weekly combination of cagrilintide with semaglutide — but "cagrilintide dosage" searches also want the monotherapy context.
Quick Answer: Cagrilintide Dosage
| Setting | Public dose anchor |
|---|---|
| CagriSema (REDEFINE obesity program) | Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly |
| Cagrilintide monotherapy arms (same program family) | Cagrilintide alone (commonly discussed at the 2.4 mg weekly level in Phase 3 comparison arms) |
| Semaglutide alone comparator | Semaglutide 2.4 mg weekly |
That 2.4 / 2.4 pairing is the SEO-stable number set — the same way "tirzepatide 15 mg" became a household phrase.
Why the Combo Dose Beat Either Alone
REDEFINE 1 public results (68 weeks, obesity/overweight without diabetes) showed the combination outperforming both monotherapies on mean weight loss. Approximate main-analysis style figures widely cited:
| Arm | Approx. mean weight change |
|---|---|
| CagriSema | ~−20% |
| Semaglutide alone | ~−15% |
| Cagrilintide alone | ~−11–12% |
| Placebo | ~−3% |
Adherence-estimating analyses pushed CagriSema even higher (low-20%s) with a large share of participants hitting ≥25% loss in public summaries.
Takeaway for dosing literacy: cagrilintide monotherapy is meaningful; pairing with GLP-1 is the headline product thesis.
Titration Reality (Not Instant 2.4 mg)
Obesity programs almost never start patients at the full maintenance combo on day one. Expect:
- Gradual escalation of one or both components
- GI monitoring at each step
- Holds for nausea/vomiting before forcing the schedule
- Long maintenance phase where 2.4 / 2.4 lives
If a future label differs, the label wins. Until then, "2.4 mg weekly amylin + 2.4 mg weekly GLP-1" is the correct public mental model for CagriSema.
Do Not Cross-Convert to Eloralintide Milligrams
| Drug | Public weekly anchors |
|---|---|
| Cagrilintide (CagriSema) | 2.4 mg |
| Eloralintide Phase 2 | 1–9 mg |
| Petrelintide Phase 2 | five weekly arms (mg table pending full release) |
Different molecules. Matching numbers is cargo-cult pharmacology.
Side Effects and Tracking
Expect amylin + GLP-1 GI overlap:
- Nausea, early fullness, constipation
- Risk of under-eating protein
- Dose-day symptom spikes during escalation
Track:
- Which component changed this week
- 0–10 nausea for 72 hours
- Protein grams + lifts
- Average weight / waist
- Hydration and bowel pattern
FAQ
Q: What is the cagrilintide dose in CagriSema?
A: Public Phase 3 obesity communications center on 2.4 mg cagrilintide with 2.4 mg semaglutide once weekly at maintenance.
Q: Is cagrilintide used alone?
A: Yes in trial arms — and it produced solid but generally smaller mean loss than the combo in REDEFINE 1 summaries.
Q: Is CagriSema FDA-approved?
A: Check current regulatory status with a clinician and official sources; submission/review status has moved quickly and can differ from consumer assumptions.
Q: Can I add cagrilintide to tirzepatide myself?
A: Unsupervised dual-pathway stacking is not the same as a studied fixed combo. Clinical guidance required.
Bottom Line
Cagrilintide dosing for search intent almost always means the 2.4 mg weekly amylin piece of CagriSema — powerful alone, stronger with semaglutide 2.4 mg. Learn that pair, track titration honestly, and refuse milligram conversions to Lilly or Roche amylin agonists.
Download PeptIQ to log combo metabolic doses as separate components.
Educational content only. Not medical advice.
